Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 15357 | 16.72 |
09:34 ET | 1205 | 16.76 |
09:36 ET | 555 | 16.76 |
09:38 ET | 3192 | 16.7945 |
09:39 ET | 13943 | 16.97 |
09:41 ET | 15530 | 16.93 |
09:43 ET | 4054 | 16.92 |
09:45 ET | 8819 | 16.82 |
09:48 ET | 1793 | 16.85 |
09:50 ET | 6539 | 16.84 |
09:52 ET | 10310 | 16.87 |
09:54 ET | 8800 | 16.85 |
09:56 ET | 1841 | 16.78 |
09:57 ET | 4162 | 16.785 |
09:59 ET | 2809 | 16.8 |
10:01 ET | 5040 | 16.76 |
10:03 ET | 4150 | 16.75 |
10:06 ET | 6900 | 16.73 |
10:08 ET | 1926 | 16.76 |
10:10 ET | 4135 | 16.75 |
10:12 ET | 3700 | 16.725 |
10:14 ET | 13360 | 16.695 |
10:15 ET | 5093 | 16.73 |
10:17 ET | 4848 | 16.69 |
10:19 ET | 4311 | 16.67 |
10:21 ET | 1200 | 16.6327 |
10:24 ET | 862 | 16.62 |
10:26 ET | 1450 | 16.6099 |
10:28 ET | 22541 | 16.6133 |
10:30 ET | 4827 | 16.6 |
10:32 ET | 15933 | 16.56 |
10:33 ET | 6830 | 16.55 |
10:35 ET | 10699 | 16.52 |
10:37 ET | 11539 | 16.46 |
10:39 ET | 11199 | 16.47 |
10:42 ET | 2921 | 16.46 |
10:44 ET | 17503 | 16.5 |
10:46 ET | 17051 | 16.48 |
10:48 ET | 11627 | 16.5 |
10:50 ET | 1886 | 16.54 |
10:51 ET | 1989 | 16.58 |
10:53 ET | 1684 | 16.57 |
10:55 ET | 200 | 16.55 |
10:57 ET | 100 | 16.55 |
11:00 ET | 1347 | 16.56 |
11:02 ET | 1251 | 16.56 |
11:04 ET | 800 | 16.56 |
11:06 ET | 1603 | 16.5466 |
11:08 ET | 300 | 16.53 |
11:09 ET | 6067 | 16.45 |
11:11 ET | 6604 | 16.51 |
11:13 ET | 11750 | 16.49 |
11:15 ET | 14064 | 16.51 |
11:18 ET | 6506 | 16.51 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.6B | 74.9x | --- |
ADMA Biologics Inc | 2.5B | -521.8x | --- |
Twist Bioscience Corp | 3.1B | -15.1x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.0x | --- |
MorphoSys AG | 2.8B | -5.3x | --- |
Vericel Corp | 2.1B | 4,418.4x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.22 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 74.9x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | 62.8x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.